Children, parents over-report leukemia treatment adherence

February 2, 2017, American Society of Hematology
Pill bottle fitted with MEMSTMTrackCap to electronically monitor a patient's 6MP intake. Credit: © 2017 The American Society of Hematology

New research suggests that young patients with acute lymphocytic leukemia (ALL)—the most common type of pediatric cancer—and their and their parents are likely to report to their physician that they took more of their anti-cancer medication than they actually did.

The study, published online today in Blood the Journal of the American Society of Hematology (ASH), reports that 84 percent of with ALL or their parents over-reported adherence to a regimen of 6-mercaptopurine (6MP), an oral maintenance therapy for pediatric ALL. Physicians prescribe 6MP for two years after chemotherapy for patients to achieve durable remissions, but studies show that over 95 percent of prescribed doses must be taken to be effective.

"Because this therapy is administered orally every day, we cannot supervise our patients to make sure they are taking their pills," said senior study author Smita Bhatia, MD, MPH, of the University of Alabama at Birmingham. "Findings from this study suggest that we need better ways to monitor intake of medications as prescribed."

This study builds on trends observed among children with chronic illness with at-home treatment regimens, and is the first to directly compare self-reporting against electronic monitoring in pediatric cancer patients.

Dr. Bhatia and colleagues gave 416 pediatric ALL patients from 87 participating institutions across the United States prescription pill bottles for their 6MP that contained a microprocessor chip in the cap to log the date and time the bottle was opened. These logs were then compared against self-report questionnaires completed by patients or their parents and provided to their physicians at monthly check-ups.

In addition to observing a majority of patients over-reporting the number of days that they had taken their medications, researchers observed a direct inverse trend in over-reporting. Of those found to adhere to their regimens (defined as taking their prescribed dose 95% of the time), a small percentage (8%) over-reported their intake. However, among those found non-adherent, a substantially larger percent (47%) over-reported. "We observed that there was an inverse relationship between over-reporting and the extent of non-adherence," said Dr. Bhatia.

In order to find out why patients were not taking their prescribed medication, lead study author Wendy Landier, PhD, RN, also of the University of Alabama at Birmingham, organized separate one-on-one interviews with patients and their parents. In these interviews, Dr. Landier noted that forgetfulness was the primary reason for non-adherence. "We found that partnering with a parent was very conducive to our patients' adherence, playing a key role in combatting forgetfulness," said Dr. Landier.

Recognizing the importance of parental involvement in patient adherence, the team was inspired to conduct further research to make parents more involved. In a trial that builds on this study, physicians send personalized text messages to both patients and their parents at a prescribed time reminding them to take their medicine. Both patient and parent then report back, via text, that the indicated dose was taken.

"Our first study showed that non-adherence was prevalent, increasing the risk of relapse. We then found that parental vigilance was an important facilitator to adherence, while forgetting to take the medication was the most commonly reported barrier. We used these findings to inform the intervention trial to help families improve adherence to treatment. We hope that this will be a real step in improving outcomes in children with leukemia," said Dr. Bhatia.

Explore further: One in four children with leukemia not taking maintenance medication, study shows

More information: Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: A Children's Oncology Group study, Blood 2017 :blood-2016-07-726893 , doi.org/10.1182/blood-2016-07-726893

Related Stories

One in four children with leukemia not taking maintenance medication, study shows

June 2, 2014
An estimated 25 percent of children in remission from acute lymphocytic leukemia (ALL) are missing too many doses of an essential maintenance medication that minimizes their risk of relapse, according to a study published ...

Plan A is to get patients to stick to their blood pressure pills

January 19, 2017
There is value in starting off patients with high blood pressure on an all-in-one pill. In the long run, it may help them stick to taking the potentially life-saving medicines prescribed to them. This advice is given to clinicians ...

Diabetes medication adherence, language, glycemic control in Latino patients

January 23, 2017
JAMA Internal Medicine is publishing two articles and an editorial focusing on Latino patients with type 2 diabetes.

Importance of drug as assessed by doctor not tied to adherence

September 15, 2016
(HealthDay)—Physician-assessed drug importance is not associated with patient-reported drug adherence, according to a study published in the September/October issue of the Annals of Family Medicine.

Impact of cognitive functions on oral cancer therapies

October 4, 2016
The development of oral cancer drugs as a modality therapy over the last decade has highlighted the problem of non-adherence. Only cancer drugs that are taken can actually work. Contrary to what is expected, a significant ...

Physicians don't adequately monitor patients' medication adherence

July 16, 2012
Patients' non-adherence to prescribed medication costs the U.S. health care system an estimated $290 billion annually and can lead to poor clinical outcomes, increased hospitalizations and higher mortality.

Recommended for you

Scientists identify 170 potential lung cancer drug targets using unique cellular library

April 19, 2018
After testing more than 200,000 chemical compounds, UT Southwestern's Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.

Discovery adds to evidence that some children are predisposed to develop leukemia

April 19, 2018
St. Jude Children's Research Hospital researchers have made a discovery that expands the list of genes to include when screening individuals for possible increased susceptibility to childhood leukemia. The finding is reported ...

Mechanism that drives development of liver cancer brought on by non-alcoholic fatty liver disease discovered

April 19, 2018
A team of researchers from several institutions in China has found a mechanism that appears to drive the development of a type of liver cancer not caused by alcohol consumption. In their paper published in the journal Science ...

Chip-based blood test for multiple myeloma could make bone biopsies a relic of the past

April 19, 2018
The diagnosis and treatment of multiple myeloma, a cancer affecting plasma cells, traditionally forces patients to suffer through a painful bone biopsy. During that procedure, doctors insert a bone-biopsy needle through an ...

Study may explain why some triple-negative breast cancers are resistant to chemotherapy

April 19, 2018
Triple-negative breast cancer (TNBC) is an aggressive form of the disease accounting for 12 to 18 percent of breast cancers. It is a scary diagnosis, and even though chemotherapy can be effective as standard-of-care, many ...

Protein can slow intestinal tumor growth

April 19, 2018
A new mechanism for regulating stem cells in the intestine of fruit flies has been discovered by researchers at Stockholm University. In addition, it was discovered that a certain protein can slow the growth of tumours in ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.